Ozempic (semaglutide) highlights of prescribing information, Food and Drug Administration (2025) FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk USA (2025) Alcohol-associated liver disease, Johns Hopkins Medicine (2025) Nonalcoholic fatty liver disease (NAFLD) & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Symptoms & causes of NAFLD & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Efficacy and safety of semaglutide in non-alcoholic fatty liver disease, World Journal of Gastroenterology (2023) Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2023) GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives, International Journal of Molecular Sciences (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease, Hepatology (2023) Rezdiffra (resmetirom) highlights of prescribing information, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
The current Triple agonists in Phase 2 and Phase 3 development have recorded even better results with early trials with some of the candidates showing weight loss up to 27% in clinical trials and this was comparable to the effects of bariatric surgery without surgery
In one embodiment, water-soluble glycerin-based auris-acceptable enhanced viscosity formulations utilized in the preparation of pharmaceutical delivery vehicles comprise at least one active agent containing at least about 0.1% of the water-soluble glycerin compound or more
These are well-documented side effects of significant caloric restriction regardless of how that restriction is achieved
